Under terms of the sale, French firm Servier S.A.S will pay $2.4bn (€1.94bn) in cash for Shire’s in-market products indicated to treat various types of cancer, as well its oncology-focused pipeline.

https://www.biopharma-reporter.com/Article/2018/04/16/Shire-sells-cancer-biz-for-2.4bn?utm_source=newsletter_daily&utm_medium=email&utm_campaign=GIN_IPd&c=B5LaTvdHM6C%2BfC49C3JtEgurhiMQsAUN&p2=